脂氧合酶与细胞色素P450产物升高预测慢性肾脏病进展
在CRIC研究子队列中,比较123例进展至终末期肾病的CKD患者与177例未进展者的85种花生四烯酸代谢产物。基线15-HETE和20-HETE在进展者中显著升高,校正后仅20-HETE独立预测CKD进展,每增加1个标准差进展风险高45%。
要点
- 基线20-HETE升高与CKD进展至ESKD风险独立相关。
- 15-HETE在进展者中升高,但校正后未独立预测进展。
- 脂氧合酶和细胞色素P450通路主成分与CKD进展独立相关。
核心结论
- 较高的20-HETE水平及LOX和CYP450代谢通路活性与CKD进展风险升高相关。
研究设计与样本
- CRIC研究子队列,123例进展至ESKD者与177例未进展者按频率匹配,用质谱法检测基线血清类花生酸。
主要发现
- 进展者基线15-HETE和20-HETE水平显著升高(FDR Q ≤ 0.026)。
- 进展者20-HETE中位数7.6 pmol/mL(IQR 4.2-14.5),非进展者5.4 pmol/mL(IQR 2.8-9.4),P < 0.001。
- 校正模型中仅20-HETE独立预测CKD进展,每增加1个标准差OR 1.45(95%CI 1.07-1.95;P = 0.017)。
- LOX和CYP450通路主成分与CKD进展独立相关。
临床怎么用
- 20-HETE及LOX/CYP450通路产物可能作为识别CKD进展高风险患者的生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical relevance of arachidonic acid (AA) metabolites in chronic kidney disease (CKD) progression is poorly understood. We aimed to compare the concentrations of 85 enzymatic pathway products of AA metabolism in patients with CKD who progressed to end-stage kidney disease (ESKD) versus patients who did not in a subcohort of Chronic Renal Insufficiency Cohort (CRIC) and to estimate the risk of CKD progression and major cardiovascular events by levels of AA metabolites and their link to enzymatic metabolic pathways. METHODS: A total 123 patients in the CRIC study who progressed to ESKD were frequency matched with 177 nonprogressors and serum eicosanoids were quantified by mass spectrometry. We applied serum collected at patients' Year 1 visit and outcome of progression to ESKD was ascertained over the next 10 years. We used logistic regression models for risk estimation. RESULTS: Baseline 15-hydroxyeicosatetraenoate (HETE) and 20-HETE levels were significantly elevated in progressors (false discovery rate Q ≤ 0.026). The median 20-HETE level was 7.6 pmol/mL [interquartile range (IQR) 4.2-14.5] in progressors and 5.4 pmol/mL (IQR 2.8-9.4) in nonprogressors (P < 0.001). In an adjusted model, only 20-HETE independently predicted CKD progression. Each 1 standard deviation increase in 20-HETE was independently associated with 1.45-fold higher odds of progression (95% confidence interval 1.07-1.95; P = 0.017). Principal components of lipoxygenase (LOX) and cytochrome P450 (CYP450) pathways were independently associated with CKD progression. CONCLUSIONS: We found higher odds of CKD progression associated with higher 20-HETE, LOX and CYP450 metabolic pathways. These alterations precede CKD progression and may serve as targets for interventions aimed at halting progression.
引用
- Afshinnia F, Zeng L, Byun J, et al. Elevated lipoxygenase and cytochrome P450 products predict progression of chronic kidney disease. Nephrol Dial Transplant. 2020. PMID: 30137494. doi:10.1093/ndt/gfy232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。